Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Present with type 2 diabetes~* Patients have been treated with a stable dose of the following for at least 3 months prior to screening:~  * 100 mg/day sitagliptin and~ * ≥1500 mg/day metformin, or maximum tolerated dose (extended release or immediate-release).~* Have inadequate glycemic control as evidenced by an HbA1c between 7.1% and 9%, inclusive.~* Have a body mass index (BMI) ≥20 kg/m2 and \<45 kg/m2~Exclusion Criteria:~* Are currently enrolled in, or discontinued within the last 30 days (or longer, if local guidelines require) from, a clinical trial involving an off-label use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.~* Have previously completed or withdrawn from this study or any other study investigating exenatide.~* Have a known allergy or hypersensitivity to exenatide, sitagliptin or excipients contained in exenatide or sitagliptin.~* Used drugs for weight loss (for example, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 1 month of screening.~* Are currently treated with any of the following excluded medications:~  * Thiazolidinediones (TZD) within 3 months of screening.~ * Sulfonylurea (SU) within 3 months of screening.~ * Dipeptidyl peptidase-4 \[DPP-4\] inhibitors, with the exception of sitagliptin, within 3 months of screening.~ * Meglitinide derivatives (for example, repaglinide or nateglinide) within 3 months of screening.~ * Alpha-glucosidase inhibitors (for example, miglitol or acarbose) within 3 months of screening.~ * Exogenous insulin within the 3 months prior to screening.~ * Drugs that directly affect gastrointestinal motility, including, but not limited to: metoclopramide, cisapride, and chronic macrolide antibiotics.~ * Systemic corticosteroids (excluding topical and inhaled preparations) by oral, intravenous (IV), or intramuscular (IM) route used regularly (for longer than 1 month) or used within 1 month immediately prior to screening.~ * Any other oral antidiabetic (OAD) agent, other than sitagliptin or metformin, within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).